MX2020007032A - Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma. - Google Patents
Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma.Info
- Publication number
- MX2020007032A MX2020007032A MX2020007032A MX2020007032A MX2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A MX 2020007032 A MX2020007032 A MX 2020007032A
- Authority
- MX
- Mexico
- Prior art keywords
- ige
- composition
- probiotics
- polypeptide
- binding affinity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición que contiene, como ingredientes activos, probióticos y un polipéptido con capacidad de unión a IgE. En particular, se identificó un efecto sinérgico de disminución notable de la alergia alimentaria en el momento de la administración combinada de probióticos y una proteína recombinante que contiene un dominio extracelular de una subunidad alfa de un receptor Fc de IgE de conformidad con la presente invención. Por lo tanto, se espera que la composición de la presente invención sea altamente aplicable industrialmente debido a que puede presentar un efecto terapéutico notable sobre una enfermedad alérgica mediada por IgE en comparación con las composiciones farmacéuticas convencionales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180004421 | 2018-01-12 | ||
PCT/KR2019/000524 WO2019139434A1 (ko) | 2018-01-12 | 2019-01-14 | 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007032A true MX2020007032A (es) | 2020-12-03 |
Family
ID=67218660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007032A MX2020007032A (es) | 2018-01-12 | 2019-01-14 | Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220347236A1 (es) |
EP (1) | EP3738599B1 (es) |
JP (1) | JP7041272B2 (es) |
KR (1) | KR102038679B1 (es) |
CN (1) | CN111587118B (es) |
AU (1) | AU2019206205A1 (es) |
BR (1) | BR112020013818A2 (es) |
CA (1) | CA3086224A1 (es) |
CL (1) | CL2020001800A1 (es) |
ES (1) | ES2969110T3 (es) |
IL (1) | IL275593B (es) |
MX (1) | MX2020007032A (es) |
PE (1) | PE20210108A1 (es) |
PH (1) | PH12020551069A1 (es) |
SG (1) | SG11202005863TA (es) |
TW (1) | TWI737955B (es) |
WO (1) | WO2019139434A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021006599A1 (ko) * | 2019-07-08 | 2021-01-14 | (주)지아이이노베이션 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 |
EP4183803A4 (en) * | 2020-07-17 | 2024-04-17 | GI Innovation, Inc. | FUSION PROTEIN WITH EXTRACELLULAR DOMAIN OF IGE-FC RECEPTOR ALPHA SUBUNIT AND ANTI-IL-4R ANTIBODIES AND USE THEREOF |
KR20220011931A (ko) * | 2020-07-22 | 2022-02-03 | (주)지아이이노베이션 | IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH092959A (ja) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | IgE抗体産生抑制剤および抗アレルギー剤 |
JPH10309178A (ja) * | 1997-05-09 | 1998-11-24 | Wakamoto Pharmaceut Co Ltd | ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品 |
JP2000095697A (ja) | 1998-09-18 | 2000-04-04 | Advance Co Ltd | 抗アレルギー剤 |
AUPQ415899A0 (en) * | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
EP1239032A1 (en) * | 2001-03-02 | 2002-09-11 | Société des Produits Nestlé S.A. | Lactic acid bacteria as agents for treating and preventing allergy |
JP2009067679A (ja) | 2005-12-27 | 2009-04-02 | Univ Of Tokushima | 抗ヒスタミン作用を有する医薬 |
WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
EP2097452A1 (en) | 2006-12-14 | 2009-09-09 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
EP2162472B1 (en) | 2007-05-30 | 2013-02-27 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
EP2065048A1 (en) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
AU2009212295A1 (en) | 2008-02-06 | 2009-08-13 | The Procter & Gamble Company | Compositions methods and kits for enhancing immune response to a respiratory condition |
WO2010013143A2 (en) * | 2008-08-01 | 2010-02-04 | Institut Pasteur | Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus |
ES2742419T3 (es) | 2008-09-17 | 2020-02-14 | Xencor Inc | Nuevas composiciones y métodos para tratar trastornos mediados por IgE |
AU2010315470B2 (en) * | 2009-10-26 | 2016-05-05 | Genentech, Inc. | Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis |
WO2012169735A2 (ko) * | 2011-06-07 | 2012-12-13 | (주)네오팜 | FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물 |
KR20120135865A (ko) * | 2011-06-07 | 2012-12-17 | (주)네오팜 | FcεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IgE 매개 알레르기성 질환 치료용 조성물 |
CN103169733B (zh) * | 2011-12-26 | 2014-11-12 | 浙江贝因美科工贸股份有限公司 | 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂 |
TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Fc融合高親和性IgE受體α鏈 |
JP2018515426A (ja) * | 2015-03-12 | 2018-06-14 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 細菌組成物およびその使用方法 |
KR101778734B1 (ko) | 2016-03-11 | 2017-09-18 | 대한민국(농촌진흥청장) | 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물 |
US20210070833A1 (en) * | 2018-01-08 | 2021-03-11 | Gl INNOVATION, INC. | Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same |
-
2019
- 2019-01-14 PE PE2020000943A patent/PE20210108A1/es unknown
- 2019-01-14 CA CA3086224A patent/CA3086224A1/en active Pending
- 2019-01-14 KR KR1020190004610A patent/KR102038679B1/ko active IP Right Grant
- 2019-01-14 BR BR112020013818-5A patent/BR112020013818A2/pt unknown
- 2019-01-14 US US16/959,016 patent/US20220347236A1/en active Pending
- 2019-01-14 JP JP2020537681A patent/JP7041272B2/ja active Active
- 2019-01-14 SG SG11202005863TA patent/SG11202005863TA/en unknown
- 2019-01-14 MX MX2020007032A patent/MX2020007032A/es unknown
- 2019-01-14 WO PCT/KR2019/000524 patent/WO2019139434A1/ko unknown
- 2019-01-14 EP EP19738433.2A patent/EP3738599B1/en active Active
- 2019-01-14 AU AU2019206205A patent/AU2019206205A1/en active Pending
- 2019-01-14 CN CN201980008124.5A patent/CN111587118B/zh active Active
- 2019-01-14 ES ES19738433T patent/ES2969110T3/es active Active
- 2019-01-14 TW TW108101372A patent/TWI737955B/zh active
-
2020
- 2020-06-22 IL IL275593A patent/IL275593B/en unknown
- 2020-07-03 CL CL2020001800A patent/CL2020001800A1/es unknown
- 2020-07-10 PH PH12020551069A patent/PH12020551069A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3738599B1 (en) | 2023-12-27 |
JP2021510689A (ja) | 2021-04-30 |
KR102038679B1 (ko) | 2019-10-30 |
CN111587118A (zh) | 2020-08-25 |
US20220347236A1 (en) | 2022-11-03 |
EP3738599A1 (en) | 2020-11-18 |
CA3086224A1 (en) | 2019-07-18 |
IL275593A (en) | 2020-08-31 |
IL275593B (en) | 2022-01-01 |
KR20190086396A (ko) | 2019-07-22 |
ES2969110T3 (es) | 2024-05-16 |
AU2019206205A1 (en) | 2020-06-25 |
CL2020001800A1 (es) | 2020-10-30 |
WO2019139434A1 (ko) | 2019-07-18 |
PH12020551069A1 (en) | 2021-09-06 |
CN111587118B (zh) | 2023-11-21 |
RU2020122021A (ru) | 2022-02-14 |
BR112020013818A2 (pt) | 2020-12-01 |
SG11202005863TA (en) | 2020-07-29 |
TWI737955B (zh) | 2021-09-01 |
PE20210108A1 (es) | 2021-01-19 |
EP3738599C0 (en) | 2023-12-27 |
EP3738599A4 (en) | 2021-10-27 |
JP7041272B2 (ja) | 2022-03-23 |
TW201932129A (zh) | 2019-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551069A1 (en) | Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof | |
MX2021010809A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
WO2018115003A3 (en) | Novel tnfr agonists and uses thereof | |
MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
EA202091342A2 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
MX2018005194A (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
GT201500049A (es) | Proteinas de fusiòn para el tratamiento de un sìndrome metàbolico | |
TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
MY162324A (en) | Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections | |
MX2020014031A (es) | Proteinas heterodimericas y usos de las mismas. | |
MY194925A (en) | Composition of fish skin collagen peptides and use thereof as a drug | |
CR20220618A (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
PH12020551021A1 (en) | Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same | |
MX347229B (es) | Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso. | |
BR112017025000A2 (pt) | tratamento de hipoglicemia pós-bariátrica com exendina (9-39) | |
PH12020551500A1 (en) | Viscosity reduction of highly concentrated protein formulations | |
MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
PT3774859T (pt) | Composições de proteína de fusão recombinante de neuregulina-1 (nrg-1) humana e métodos de uso das mesmas | |
MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
MX2019005874A (es) | Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg. | |
MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
MX2020010030A (es) | Metodos y composiciones que comprenden proteina d tensoactiva (sp-d). |